Harvard Bioscience - HBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 173.44 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.56
▼ -0.04 (-1.54%)

This chart shows the closing price for HBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harvard Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HBIO

Analyst Price Target is $7.00
▲ +173.44% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Harvard Bioscience in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 173.44% upside from the last price of $2.56.

This chart shows the closing price for HBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Harvard Bioscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022KeyCorpLower TargetOverweight$10.00 ➝ $7.00Low
3/10/2021KeyCorpBoost Target$6.00 ➝ $9.00High
1/7/2021BenchmarkUpgradeSpeculative Buy ➝ BuyN/A
12/9/2020Northland SecuritiesInitiated CoverageOutperformHigh
11/9/2020KeyCorpInitiated CoverageOverweightMedium
2/27/2020BenchmarkBoost TargetSpeculative Buy$3.50 ➝ $4.00High
12/9/2019BenchmarkDowngradeBuyHigh
7/19/2019BenchmarkReiterated RatingBuyN/A
7/8/2019Janney Montgomery ScottDowngradeBuy ➝ Neutral$2.00High
2/18/2019Janney Montgomery ScottReiterated RatingBuyLow
6/30/2018BenchmarkInitiated CoverageBuy$11.00Low
4/16/2018BenchmarkSet TargetBuy$10.00High
1/24/2018Janney Montgomery ScottBoost TargetBuy ➝ Buy$5.00 ➝ $8.00Low
1/23/2018BenchmarkBoost TargetBuy ➝ Buy$6.00 ➝ $10.00High
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 43 positive mentions
  • 14 negative mentions
  • 6 very negative mentions
3/6/2022
  • 7 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
4/5/2022
  • 4 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/4/2022
  • 3 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
7/4/2022
  • 13 very positive mentions
  • 34 positive mentions
  • 15 negative mentions
  • 14 very negative mentions
8/3/2022
  • 6 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
9/2/2022
  • 5 very positive mentions
  • 34 positive mentions
  • 11 negative mentions
  • 4 very negative mentions
10/2/2022

Current Sentiment

  • 5 very positive mentions
  • 34 positive mentions
  • 11 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Harvard Bioscience logo
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Read More

Today's Range

Now: $2.56
Low: $2.55
High: $2.74

50 Day Range

MA: $3.19
Low: $2.33
High: $3.81

52 Week Range

Now: $2.56
Low: $2.27
High: $8.23

Volume

111,322 shs

Average Volume

134,369 shs

Market Capitalization

$106.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Harvard Bioscience?

The following Wall Street analysts have issued reports on Harvard Bioscience in the last twelve months: KeyCorp, StockNews.com, and TheStreet.
View the latest analyst ratings for HBIO.

What is the current price target for Harvard Bioscience?

1 Wall Street analysts have set twelve-month price targets for Harvard Bioscience in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 173.4%. KeyCorp has the highest price target set, predicting HBIO will reach $7.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $7.00 for Harvard Bioscience in the next year.
View the latest price targets for HBIO.

What is the current consensus analyst rating for Harvard Bioscience?

Harvard Bioscience currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HBIO will outperform the market and that investors should add to their positions of Harvard Bioscience.
View the latest ratings for HBIO.

What other companies compete with Harvard Bioscience?

How do I contact Harvard Bioscience's investor relations team?

Harvard Bioscience's physical mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier's listed phone number is (508) 893-8999 and its investor relations email address is [email protected] The official website for Harvard Bioscience is www.harvardbioscience.com. Learn More about contacing Harvard Bioscience investor relations.